Head-To-Head Comparison: Bain Capital Specialty Finance (NYSE:BCSF) & Advanced Medical Isotope (OTCMKTS:RDGL)

Bain Capital Specialty Finance (NYSE:BCSF) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Bain Capital Specialty Finance and Advanced Medical Isotope, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bain Capital Specialty Finance	0	1	1	0	2.50
Advanced Medical Isotope	0	0	0	0	0.00

Bain Capital Specialty Finance presently has a consensus target price of $16.50, suggesting a potential upside of 10.78%. Given Bain Capital Specialty Finance’s stronger consensus rating and higher possible upside, research analysts plainly believe Bain Capital Specialty Finance is more favorable than Advanced Medical Isotope.

Earnings and Valuation

This table compares Bain Capital Specialty Finance and Advanced Medical Isotope”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bain Capital Specialty Finance	$292.65 million	3.30	$119.42 million	$1.74	8.56
Advanced Medical Isotope	$30,000.00	1,851.83	-$2.91 million	($0.01)	-12.25

Bain Capital Specialty Finance has higher revenue and earnings than Advanced Medical Isotope. Advanced Medical Isotope is trading at a lower price-to-earnings ratio than Bain Capital Specialty Finance, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bain Capital Specialty Finance and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bain Capital Specialty Finance	39.60%	11.62%	5.19%
Advanced Medical Isotope	-6,249.02%	N/A	-149.07%

Volatility & Risk

Bain Capital Specialty Finance has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Summary

Bain Capital Specialty Finance beats Advanced Medical Isotope on 10 of the 12 factors compared between the two stocks.

About Bain Capital Specialty Finance

Bain Capital Specialty Finance, Inc. is business development company specializing in direct loans to middle-market companies. The fund seeks to invest in senior investments with a first or second lien on collateral, senior first lien, stretch senior, senior second lien, unitranche, mezzanine debt, junior securities, other junior investments, and secondary purchases of assets or portfolios that primarily consist of middle-market corporate debt. It typically invests in companies with EBITDA between $10 million and $150 million.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.